High-Quality ADC Target Proteins

Antibody-drug conjugates (ADCs) combine cytotoxic drugs with monoclonal antibodies through linkers, merging cytotoxic potency with precise targeting, offering a promising cancer therapy. Selecting the right target is crucial. An ideal target should be tumour-specific, minimally expressed in normal tissue cells, and internalise after binding to antibodies to aid ADC-antigen complex entry into tumour cells. This process facilitates cytotoxic payload release via suitable intracellular translocation routes. Target stability and low mutational susceptibility can help alleviate the emergence of ADC resistance. Sino Biological has developed a series of ADC target protein products, including well-established targets such as HER-2, TROP-2, Nectin-4, EGFR, CD19, and BCMA, as well as emerging targets like EphA3, GFRA1, and CLEC7A. Each recombinant target boasts validated antibody-binding activity, multiple species, and various tags, providing robust support for ADC drug development.